Elevation of P-glycoprotein function by a catechin in green tea

Biochemical and Biophysical Research Communications

Volumn 297, Issue 2, 2002, Pages 412-418

  Wang, Er jia ^a   Barecki Roach, Mary ^a   Johnson, William W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHIN; CATECHIN GALLATE; DAUNORUBICIN; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GLYCOPROTEIN P; RHODAMINE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FLUORESCENCE; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; TEA;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; ANIMALS; CATECHIN; CELL LINE; FLUORESCENT DYES; HUMANS; MICE; ORGANIC CHEMICALS; P-GLYCOPROTEIN; RHODAMINE 123; TEA;

EID: 0036399061     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02219-2     Document Type: Article

References (34)

1. M.M. Gottesman, I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem. 62 (1993) 385-427.
2. M.M. Gottesman, I. Pastan, S.V. Ambudkar, P-glycoprotein and multidrug resistance, Curr. Opin. Genet. Dev. 6 (1996) 610-617.
3. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, M.M. Gottesman, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398.
4. F.J. Sharom, X. Yu, C.A. Doige, Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein, J. Biol. Chem. 268 (1993) 24197-24202.
5. A.E. Senior, S. Bhagat, P-glycoprotein shows strong catalytic cooperativity between the two nucleotide sites, Biochemistry 37 (3) (1998) 831-836.
6. A.B. Shapiro, V. Ling, Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities, Eur. J. Biochem. 250 (1997) 130-137.
7. F.J. Sharom, R. Liu, Y. Romsicki, P. Lu, Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies, Biochim. Biophys. Acta 1461 (2) (1999) 327-345.
8. A.B. Shapiro, V. Ling, Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein, Eur. J. Biochem. 250 (1997) 122-129.
9. C. Pascaud, M. Garrigos, S. Orlowski, Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents, Biochem. J. 333 (1998) 351-358.
10. T. Litman, T. Zeuthen, T. Skovsgaard, W. Stein, Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity, Biochim. Biophys. Acta 1361 (1997) 169-176.
11. E.-J. Wang, C.N. Casciano, R.P. Clement, W.W. Johnson, Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependency, Biochim. Biophys. Acta 1481 (2000) 63-74.
12. S. Dey, M. Ramachandra, I. Pastan, M.M. Gottesman, Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein, Proc. Natl. Acad. Sci. USA 94 (1997) 10594-10599.
13. G. Wang, R. Pincheira, J.-T. Zhang, Dissection of drug-binding-induced conformational changes in P-glycoprotein, Eur. J. Biochem. 255 (1998) 383-390.
14. C.A. Hrycyna, M. Ramachandra, U.A. Germann, P.W. Cheng, I. Pastan, M.M. Gottesman, Both ATP sites of human P-glycoprotein are essential but not symmetric, Biochemistry 38 (1999) 13887-13899.
15. T.W. Loo, D.M. Clarke, Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity, J. Biol. Chem. 270 (1995) 22957-22961.
16. E.-J. Wang, C.N. Casciano, R.P. Clement, W.W. Johnson, Cooperativity in the inhibition of P-glycoprotein-mediated dauno-rubicin transport: evidence for half-of-the-sites reactivity, Arch. Biochem. Biophys. 383 (1) (2000) 91-98.
17. C.S. Yang, P. Maliakal, X. Meng, Inhibition of carcinogenesis by tea, Annu. Rev. Pharmacol. Toxicol. 42 (2002) 25-54.
18. E.-J. Wang, C.N. Casciano, R.P. Clement, W.W. Johnson, In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein, Drug Metab. Disp. 28 (2000) 522-528.
19. E.-J. Wang, C.N. Casciano, R.P. Clement, W.W. Johnson, Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors, Biochem. Biophys. Res. Commun. 289 (2001) 580-585.
20. G.D. Eytan, R. Regev, Y.G. Assaraf, Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis, J. Biol. Chem. 271 (6) (1996) 3172-3178.
21. S.V. Ambudkar, C.O. Cardarelli, I. Pashinsky, W.D. Stein, Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein, J. Biol. Chem. 272 (34) (1997) 21160-21166.
22. W.D. Stein, Kinetics of the multidrug transporter (P-glycoprotein) and its reversal, Physiol. Rev. 77 (2) (1997) 545-590.
23. A.B. Shapiro, V. Ling, Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein, Eur. J. Biochem. 254 (1) (1998) 189-193.
24. Z.E. Sauna, S.V. Ambudkar, Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein, Proc. Natl. Acad. Sci. USA 97 (6) (2000) 2515-2520.
25. Z.E. Sauna, S.V. Ambudkar, Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein: the two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes, J. Biol. Chem. 276 (15) (2001) 11653-11661.
26. J. Jodoin, M. Demeule, R. Beliveau, Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols, Biochim. Biophys. Acta 1542 (1-3) (2002) 149-159.
27. R.V. Kondratov, P.G. Komarov, Y. Becker, A. Ewenson, A.V. Gudkov, Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein, Proc. Natl. Acad. Sci. USA 98 (24) (2001) 14078-14083.
28. F.J. Sharom, X. Yu, G. DiDiodato, J.W. Chu, Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport, Biochem. J. 320 (Pt 2) (1996) 421-428.
29. A.B. Shapiro, K. Fox, P. Lam, V. Ling, Stimulation of P-glycoprotein-mediated drug transport by prazosin and progester-one. Evidence for a third drug-binding site, Eur. J. Biochem. 259 (3) (1999) 841-850.
30. A.R. Safa, S. Roberts, M. Agresti, R.L. Fine, Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells, Biochem. Biophys. Res. Commun. 202 (1) (1994) 606-612.
31. 125I]iodophenethyl)spiperone binds to specific regions of P-glycoprotein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells, Biochemistry 33 (1) (1994) 256-265.
32. C. Martin, G. Berridge, C.F. Higgins, P. Mistry, P. Charlton, R. Callaghan, Communication between multiple drug binding sites on P-glycoprotein, Mol. Pharmacol. 58 (3) (2000) 624-632.
33. L. Lu, F. Leonessa, R. Clarke, I.W. Wainer, Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase, Mol. Pharmacol. 59 (1) (2001) 62-68.
34. M. Guiral, O. Viratelle, H.V. Westerho-, J. Lankelma, Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles, FEBS Lett. 346 (2-3) (1994) 141-145.